{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:50:29Z","timestamp":1774450229376,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,4,26]],"date-time":"2013-04-26T00:00:00Z","timestamp":1366934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s40265-013-0051-1","type":"journal-article","created":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T22:49:45Z","timestamp":1367362185000},"page":"575-593","source":"Crossref","is-referenced-by-count":32,"title":["Insulin Degludec and Insulin Degludec\/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus"],"prefix":"10.1007","volume":"73","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,26]]},"reference":[{"issue":"1","key":"51_CR1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/dc08-9026","volume":"32","author":"JS Skyler","year":"2009","unstructured":"Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187\u201392.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"51_CR2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association. Standard of medical care in diabetes: 2013. Diabetes Care. 2013;36(Suppl 1):S11\u201366.","journal-title":"Diabetes Care"},{"issue":"5","key":"51_CR3","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2007.00756.x","volume":"9","author":"T Heise","year":"2007","unstructured":"Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9(5):648\u201359.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"51_CR4","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1742-1241.2010.02470.x","volume":"64","author":"S Arnolds","year":"2010","unstructured":"Arnolds S, Kuglin B, Kapitza C, et al. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64(10):1415\u201324.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"51_CR5","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1185\/030079906X154178","volume":"22","author":"GE Peterson","year":"2006","unstructured":"Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin. 2006;22(12):2613\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"51_CR6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1464-5491.2006.01913.x","volume":"23","author":"SG Ashwell","year":"2006","unstructured":"Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006;23(8):879\u201386.","journal-title":"Diabet Med"},{"key":"51_CR7","unstructured":"European Medicines Agency. Tresiba (insulin degludec): EU summary of product characteristics. 2013. http:\/\/www.emea.europa.eu\/ema\/ . Accessed 1 Feb 2013."},{"key":"51_CR8","unstructured":"European Medicines Agency. Ryzodeg (insulin degludec\/insulin aspart): EU summary of product characteristics. 2013. http:\/\/www.emea.europa.eu\/ema\/ . Accessed 1 Feb 2013."},{"key":"51_CR9","unstructured":"Jonassen IB, Havelund S, Ribel U, et al. Insulin degludec is a new-generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation [abstract no. 39-OR]. 70th Annual Scientific Sessions of the American Diabetes Association; Orlando, FL; 25\u201329 June 2010."},{"issue":"Suppl 1","key":"51_CR10","first-page":"S426","volume":"54","author":"P Kurtzhals","year":"2011","unstructured":"Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec [abstract no. 1049]. Diabetologia. 2011;54(Suppl 1):S426.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"51_CR11","first-page":"A250","volume":"61","author":"T Seested","year":"2012","unstructured":"Seested T, Havelund S, Jonassen IB, et al. Ultrastructural visualisation of insulin degludec multi-hexamers in the subcutaneous depot in vivo supports a unique mechanism of protraction [abstract no. 980-P]. Diabetes. 2012;61(Suppl 1):A250.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"51_CR12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.regpep.2010.07.076","volume":"16","author":"I Jonassen","year":"2010","unstructured":"Jonassen I, Hoeg-Jensen T, Havelund S, et al. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation [abstract no 380]. J Pept Sci. 2010;16(Suppl 1):32.","journal-title":"J Pept Sci"},{"issue":"Suppl 1","key":"51_CR13","first-page":"S388","volume":"53","author":"E Nishimura","year":"2010","unstructured":"Nishimura E, S\u00f8rensen AR, Hansen BF, et al. Insulin degludec: a new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential [abstract no. 974]. Diabetologia. 2010;53(Suppl 1):S388\u20139.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"51_CR14","first-page":"A228","volume":"61","author":"L Nosek","year":"2012","unstructured":"Nosek L, Coester H-V, Thomsen HF, et al. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region [abstract no. 899-P]. Diabetes. 2012;61(Suppl 1):A228.","journal-title":"Diabetes"},{"key":"51_CR15","unstructured":"Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: two different formulations (U100 and U200) are bioequivalent and show similar pharmacodynamics [abstract no. 2349-PO]. Diabetes. 2011;60 Suppl:A624."},{"issue":"Suppl 1","key":"51_CR16","first-page":"S374","volume":"55","author":"U H\u00f6velmann","year":"2012","unstructured":"H\u00f6velmann U, Heise T, Nosek L, et al. Insulin degludec 200\u00a0U\/ml is ultra-long-acting and has a flat and stable glucose-lowering effect [abstract no. 912]. Diabetologia. 2012;55(Suppl 1):S374\u20135.","journal-title":"Diabetologia"},{"issue":"10","key":"51_CR17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Nosek L, B\u00f8ttcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944\u201350.","journal-title":"Diabetes Obes Metab"},{"key":"51_CR18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/CMED.S9494","volume":"5","author":"SN Nasrallah","year":"2012","unstructured":"Nasrallah SN, Reynolds LR. Insulin degludec, the new generation basal insulin or just another basal insulin? Clin Med Insights Endocrinol Diabetes. 2012;5:31\u20137.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"2","key":"51_CR19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1021\/bi3008609","volume":"52","author":"DB Steensgaard","year":"2013","unstructured":"Steensgaard DB, Schluckebier G, Strauss HM, et al. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry (Moscow). 2013;52(2):295\u2013309.","journal-title":"Biochemistry (Moscow)"},{"issue":"8","key":"51_CR20","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1007\/s11095-012-0739-z","volume":"29","author":"I Jonassen","year":"2012","unstructured":"Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104\u201314.","journal-title":"Pharm Res"},{"issue":"18","key":"51_CR21","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.2165\/11642240-000000000-00000","volume":"72","author":"JD Robinson","year":"2012","unstructured":"Robinson JD, Neumiller JJ, Campbell RK. Can a new ultra-long acting insulin analog improve patient care? Investigating the potential role of insulin degludec. Drugs. 2012;72(18):2319\u201325.","journal-title":"Drugs"},{"issue":"11","key":"51_CR22","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.2337\/dc11-2503","volume":"35","author":"IB Hirsch","year":"2012","unstructured":"Hirsch IB, Bode B, Courreges J-P, et al. Insulin degludec\/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012;35(11):2174\u201381.","journal-title":"Diabetes Care"},{"key":"51_CR23","unstructured":"European Medicines Agency. Insulin degludec\/insulin aspart: CHMP assessment report. 2013. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002499\/WC500139013.pdf . Accessed 28 Feb 2013."},{"issue":"9","key":"51_CR24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"51_CR25","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2165\/00003495-200464170-00013","volume":"64","author":"NA Reynolds","year":"2004","unstructured":"Reynolds NA, Wagstaff AJ. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs. 2004;64(17):1957\u201374.","journal-title":"Drugs"},{"issue":"Suppl 1","key":"51_CR26","first-page":"S425","volume":"54","author":"T Heise","year":"2011","unstructured":"Heise T, H\u00f6velmann U, Nosek L, et al. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine [abstract no. 1046]. Diabetologia. 2011;54(Suppl 1):S425.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"51_CR27","first-page":"S379","volume":"55","author":"HL Haahr","year":"2012","unstructured":"Haahr HL, Arold G, Bottcher SG, et al. Insulin degludec has similar pharmacokinetic properties in subjects with renal impairment and subjects with normal renal function [abstract no. 923]. Diabetologia. 2012;55(Suppl 1):S379.","journal-title":"Diabetologia"},{"key":"51_CR28","doi-asserted-by":"crossref","unstructured":"Arold G, Kup\u010dov\u00e1 V, Thrane M, et al. Insulin degludec has similar pharmacokinetic properties in subjects with hepatic impairment when compared to subjects with normal hepatic function [abstract no. 1119-P]. Diabetes. 2012;61 Suppl:A289.","DOI":"10.1016\/j.jcjd.2012.07.328"},{"issue":"Suppl 1","key":"51_CR29","first-page":"S425","volume":"54","author":"T Danne","year":"2011","unstructured":"Danne T, Biester T, Blaesig S, et al. Ultra-long pharmacokinetic properties of insulin degludec in adults with type 1 diabetes is preserved in children and adolescents after single-dose administration [abstract no. 1047]. Diabetologia. 2011;54(Suppl 1):S425\u20136.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"51_CR30","first-page":"S379","volume":"55","author":"S Korsatko","year":"2012","unstructured":"Korsatko S, Deller S, Mader J, et al. Ultra-long pharmacokinetic properties of insulin degludec in younger adults are preserved in geriatric subjects with type 1 diabetes [abstract no. 924]. Diabetologia. 2012;55(Suppl 1):S379\u201380.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"51_CR31","first-page":"S380","volume":"55","author":"M Hompesch","year":"2012","unstructured":"Hompesch M, Morrow L, Watkins E, et al. Insulin degludec provides similar pharmacokinetic and pharmacodynamic responses in Black, White and Hispanic\/Latino patients with type 2 diabetes [abstract no. 925]. Diabetologia. 2012;55(Suppl 1):S380.","journal-title":"Diabetologia"},{"key":"51_CR32","unstructured":"European Medicines Agency. Insulin degludec: CHMP assessment report. 2013. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002498\/WC500139010.pdf . Accessed 28 Feb 2013."},{"key":"51_CR33","doi-asserted-by":"crossref","unstructured":"Bergenstal R, Bhargava A, Jain R, et al. 200\u00a0U\/mL insulin degludec improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-na\u00efve people with type 2 diabetes [abstract no. 207]. American Association of Clinical Endocrinologists 21st Annual Scientific and Clinical Congress; Philadelphia, PA; 23\u201327 May 2012.","DOI":"10.1016\/j.jcjd.2012.07.397"},{"issue":"3","key":"51_CR34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2337\/dc10-1925","volume":"34","author":"KI Birkeland","year":"2011","unstructured":"Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34(3):661\u20135.","journal-title":"Diabetes Care"},{"issue":"9769","key":"51_CR35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(10)62305-7","volume":"377","author":"B Zinman","year":"2011","unstructured":"Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011;377(9769):924\u201331.","journal-title":"Lancet"},{"issue":"9825","key":"51_CR36","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(12)60204-9","volume":"379","author":"S Heller","year":"2012","unstructured":"Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489\u201397.","journal-title":"Lancet"},{"issue":"3","key":"51_CR37","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1210\/jc.2012-3249","volume":"98","author":"C Mathieu","year":"2013","unstructured":"Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"51_CR38","first-page":"A272","volume":"61","author":"Y Onishi","year":"2012","unstructured":"Onishi Y, Park SW, Yoo SJ, et al. Insulin degludec improves glycemic control in insulin-na\u00efve patients with type 2 diabetes: results of a randomized pan-Asian trial [abstract no. 1059-P]. Diabetes. 2012;61(Suppl 1):A272.","journal-title":"Diabetes"},{"issue":"12","key":"51_CR39","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","volume":"35","author":"B Zinman","year":"2012","unstructured":"Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464\u201371.","journal-title":"Diabetes Care"},{"issue":"9825","key":"51_CR40","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","volume":"379","author":"AJ Garber","year":"2012","unstructured":"Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498\u2013507.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"51_CR41","first-page":"S22","volume":"55","author":"A Philis-Tsimikas","year":"2012","unstructured":"Philis-Tsimikas A, Del Prato S, Satman I, et al. Insulin degludec is superior to sitagliptin in improving glycaemic control in uncontrolled patients with type 2 diabetes on oral agents [abstract no. 40]. Diabetologia. 2012;55(Suppl 1):S22.","journal-title":"Diabetologia"},{"issue":"4","key":"51_CR42","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2337\/dc12-1668","volume":"36","author":"L Meneghini","year":"2013","unstructured":"Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care. 2013;36(4):858\u201364.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"51_CR43","first-page":"A307","volume":"61","author":"HW Rodbard","year":"2012","unstructured":"Rodbard HW, Handelsman Y, Cariou B, et al. Insulin degludec reduces hypoglycemia and improves health status vs. insulin glargine in insulin-na\u00efve type 2 diabetes [abstract no. 1192-P]. Diabetes. 2012;61(Suppl 1):A307\u20138.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"51_CR44","first-page":"S378","volume":"55","author":"HW Rodbard","year":"2012","unstructured":"Rodbard HW, Zinman B, Cariou B, et al. Reduced nocturnal hypoglycaemia with insulin degludec as compared to insulin glargine: results of a 2-year randomised trial in type 2 diabetes [abstract no. 920]. Diabetologia. 2012;55(Suppl 1):S378.","journal-title":"Diabetologia"},{"key":"51_CR45","unstructured":"Novo Nordisk. Comparison of NN1250 with sitagliptin in subjects with type 2 diabetes never treated with insulin [ClinicalTrials.gov identifier NCT01046110]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http:\/\/www.clinicaltrials.gov . Accessed 13 Nov 2012."},{"key":"51_CR46","unstructured":"Novo Nordisk. Comparison of NN1250 versus insulin glargine in subjects with type 2 diabetes (BEGIN\u2122) [ClinicalTrials.gov identifier NCT01059799]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http:\/\/www.clinicaltrials.gov . Accessed 13 Nov 2012."},{"key":"51_CR47","unstructured":"Novo Nordisk. Comparison of NN1250 with insulin glargine in subjects with type 2 diabetes (BEGIN\u2122) [ClinicalTrials.gov identifier NCT01068665]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http:\/\/www.clinicaltrials.gov . Accessed 15 Nov 2012."},{"issue":"2","key":"51_CR48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/dme.12086","volume":"30","author":"N Freemantle","year":"2013","unstructured":"Freemantle N, Meneghini L, Christensen T, et al. Insulin degludec improves health-related quality of life (SF-36\u00ae) compared with insulin glargine in people with type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. Diabet Med. 2013;30(2):226\u201332.","journal-title":"Diabet Med"},{"issue":"3","key":"51_CR49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2337\/dc10-1905","volume":"34","author":"T Heise","year":"2011","unstructured":"Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-na\u00efve people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34(3):669\u201374.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"51_CR50","first-page":"S390","volume":"55","author":"S Nakamura","year":"2012","unstructured":"Nakamura S, Ono Y, Rab\u00f8l R, et al. Superior glycaemic control with once-daily IDegAsp vs insulin glargine in Japanese adults with type 2 diabetes mellitus inadequately controlled with OADs: a randomised controlled, phase 3 trial [abstract no. 949]. Diabetologia. 2012;55(Suppl 1):S390.","journal-title":"Diabetologia"},{"issue":"2","key":"51_CR51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1530\/EJE-12-0293","volume":"167","author":"L Niskanen","year":"2012","unstructured":"Niskanen L, Leiter LA, Franek E, et al. Comparison of a soluble co-formulation of insulin degludec\/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol. 2012;167(2):287\u201394.","journal-title":"Eur J Endocrinol"},{"key":"51_CR52","unstructured":"Novo Nordisk. Comparison of NN5401 with insulin glargine in insulin naive subjects with type 2 diabetes (BOOST\u2122) [ClinicalTrials.gov identifier NCT01272193]. US National Institutes of Health, ClinicalTrials.gov (online). 2012. http:\/\/www.clinicaltrials.gov . Accessed 15 Nov 2012."},{"key":"51_CR53","unstructured":"US Food and Drug Administration. FDA briefing document: NDA 203313 and NDA 203314 (insulin degludec and insulin degludec\/insulin aspart. 2012. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM327015.pdf . Accessed 28 Feb 2013."},{"issue":"2","key":"51_CR54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","volume":"15","author":"R Ratner","year":"2013","unstructured":"Ratner R, Gough SCL, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175\u201384.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"51_CR55","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/01.CIR.96.6.1750","volume":"96","author":"M Muggeo","year":"1997","unstructured":"Muggeo M, Verlato G, Bonora E, et al. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation. 1997;96(6):1750\u20134.","journal-title":"Circulation"},{"key":"51_CR56","unstructured":"European Medicine Agency. Lantus (insulin glargine): EU summary of product characteristics. 2012. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000284\/WC500036082.pdf . Accessed 15 Mar 2013."},{"issue":"2","key":"51_CR57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/2042018812437181","volume":"3","author":"A Wakil","year":"2012","unstructured":"Wakil A, Atkin SL. Efficacy and safety of ultra-long-acting insulin degludec. Ther Adv Endocrinol Metab. 2012;3(2):55\u20139.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"51_CR58","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","volume":"28","author":"American Diabetes Association Workgroup on Hypoglycemia","year":"2005","unstructured":"American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycaemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245\u20139.","journal-title":"Diabetes Care"},{"key":"51_CR59","unstructured":"European Medicine Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129256.pdf . Accessed 4 Apr 2013."},{"issue":"9825","key":"51_CR60","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S0140-6736(12)60527-3","volume":"379","author":"AA Tahrani","year":"2012","unstructured":"Tahrani AA, Bailey CJ, Barnett AH. Insulin degludec: a new ultra-longacting insulin. Lancet. 2012;379(9825):1465\u20137.","journal-title":"Lancet"},{"issue":"17","key":"51_CR61","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2165\/11470200-000000000-00000","volume":"72","author":"GM Keating","year":"2012","unstructured":"Keating GM. Insulin detemir: a review of its use in the management of diabetes mellitus. Drugs. 2012;72(17):2255\u201387.","journal-title":"Drugs"},{"key":"51_CR62","unstructured":"Novo Nordisk. Novo Nordisk receives complete response letter in the US for Tresiba\u00ae and Ryzodeg\u00ae (media release). 2013. http:\/\/www.novonordisk.com\/include\/asp\/exe_news_attachment.asp?sAttachmentGUID=83700060-0ce3-4577-a35a-f3e57801637d . Accessed 7 Mar 2013."},{"key":"51_CR63","unstructured":"Pharmaceuticals and Medical Devices Agency. Insulin degludec submission file. 2013. http:\/\/www.pmda.go.jp\/index.html . Accessed 5 Apr 2013."},{"key":"51_CR64","unstructured":"Novo Nordisk. Tresiba\u00ae now ready to be launched in Japan (media release). 2013. http:\/\/novonordisk.com\/investors\/sea\/sea.asp?sNewsTypeGUID=&lMonth=&lYear=&sLanguageCode=&sSearchText=&fb=4350&cat=pr&sShowNewsItemGUID=33a77fce-8192-47d1-a360-68275268a048&sShowLanguageCode=en-GB . Accessed 4 Apr 2013."},{"issue":"7","key":"51_CR65","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674\u201385.","journal-title":"Diabetes Care"},{"issue":"12","key":"51_CR66","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1007\/s00125-009-1568-4","volume":"52","author":"A Dejgaard","year":"2009","unstructured":"Dejgaard A, Lynggaard H, R\u00e5stam J, et al. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia. 2009;52(12):2507\u201312.","journal-title":"Diabetologia"},{"issue":"8","key":"51_CR67","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1463-1326.2011.01395.x","volume":"13","author":"M Evans","year":"2011","unstructured":"Evans M, Schumm-Draeger PM, Vora J, et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13(8):677\u201384.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"51_CR68","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319\u201328.","journal-title":"N Engl J Med"},{"key":"51_CR69","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2147\/DMSO.S21979","volume":"5","author":"F Wang","year":"2012","unstructured":"Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes. 2012;5:191\u2013204.","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0051-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0051-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0051-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T02:59:03Z","timestamp":1562986743000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0051-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,26]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0051-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,26]]}}}